Amgen Inc. (AMGN) Income Statement Analysis

See more : John Wood Group PLC (WDGJF) Income Statement Analysis – Financial Results

Complete financial analysis of Amgen Inc. (AMGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amgen Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Amgen Inc. (AMGN)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.amgen.com

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1988	1987	1986	1985
Revenue	28.19B	26.32B	25.98B	25.42B	23.36B	23.75B	22.85B	22.99B	21.66B	20.06B	18.68B	17.27B	15.58B	15.05B	14.64B	15.00B	14.77B	14.27B	12.43B	10.55B	8.36B	5.52B	4.02B	3.45B	3.20B	2.64B	2.35B	2.20B	1.90B	1.62B	1.35B	1.08B	679.80M	190.40M	70.20M	44.30M	29.80M	21.10M
Cost of Revenue	8.42B	6.41B	6.45B	6.16B	4.36B	4.10B	4.07B	4.16B	4.23B	4.42B	3.35B	2.92B	2.43B	2.22B	2.09B	2.30B	2.55B	2.10B	2.08B	1.73B	1.34B	735.70M	443.00M	196.60M	225.30M	201.40M	183.70M	182.90M	188.70M	163.60M	169.30M	151.20M	91.20M	14.70M	44.00M	35.50M	21.80M	-2.50M
Gross Profit	19.78B	19.92B	19.53B	19.27B	19.01B	19.65B	18.78B	18.83B	17.44B	15.64B	15.33B	14.35B	13.16B	12.83B	12.55B	12.71B	12.22B	12.17B	10.35B	8.82B	7.02B	4.79B	3.57B	3.25B	2.98B	2.44B	2.16B	2.02B	1.72B	1.46B	1.19B	929.10M	588.60M	175.70M	26.20M	8.80M	8.00M	23.60M
Gross Profit Ratio	70.15%	75.66%	75.16%	75.77%	81.35%	82.73%	82.19%	81.90%	80.49%	77.96%	82.08%	83.10%	84.42%	85.25%	85.72%	84.70%	82.75%	85.32%	83.25%	83.59%	83.96%	86.68%	88.97%	94.30%	92.97%	92.38%	92.17%	91.68%	90.09%	89.90%	87.50%	86.00%	86.58%	92.28%	37.32%	19.86%	26.85%	111.85%
Research & Development	4.78B	4.43B	4.82B	4.21B	4.12B	3.74B	3.56B	3.84B	4.07B	4.30B	4.08B	3.38B	3.17B	2.89B	2.86B	3.03B	3.27B	3.37B	2.31B	2.03B	1.66B	1.12B	865.00M	845.00M	822.80M	663.30M	630.80M	528.30M	451.70M	323.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	5.52B	4.57B	4.53B	4.77B	4.36B	5.33B	4.87B	5.06B	4.85B	4.70B	5.18B	4.80B	4.49B	3.98B	3.82B	3.79B	3.36B	3.37B	2.79B	2.56B	1.95B	1.46B	970.70M	826.90M	654.30M	515.40M	483.80M	470.60M	418.40M	359.80M	583.70M	397.40M	0.00	134.60M	23.00M	10.30M	6.80M	22.00M
Selling & Marketing	647.00M	841.00M	843.00M	962.00M	789.00M	674.00M	620.00M	489.00M	346.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	6.18B	5.41B	5.37B	5.73B	5.15B	5.33B	4.87B	5.06B	4.85B	4.70B	5.18B	4.80B	4.49B	3.98B	3.82B	3.79B	3.36B	3.37B	2.79B	2.56B	1.95B	1.46B	970.70M	826.90M	654.30M	515.40M	483.80M	470.60M	418.40M	359.80M	583.70M	397.40M	443.70M	134.60M	23.00M	10.30M	6.80M	22.00M
Other Expenses	915.00M	503.00M	194.00M	189.00M	66.00M	314.00M	375.00M	133.00M	49.00M	454.00M	196.00M	589.00M	294.00M	411.00M	361.00M	674.00M	817.00M	370.00M	396.00M	333.00M	316.10M	-7.09B	205.80M	211.80M	176.80M	143.80M	117.10M	100.30M	84.20M	74.50M	50.70M	33.60M	21.50M	12.00M	8.00M	4.10M	2.60M	2.50M
Operating Expenses	11.88B	10.35B	10.38B	10.13B	9.33B	9.38B	8.81B	9.04B	8.97B	9.45B	9.46B	8.77B	8.84B	7.29B	7.05B	7.49B	7.44B	7.10B	5.50B	4.92B	3.92B	-4.51B	2.04B	1.88B	1.65B	1.32B	1.23B	1.10B	954.30M	757.90M	634.40M	431.00M	465.20M	146.60M	31.00M	14.40M	9.40M	24.50M
Cost & Expenses	20.29B	16.76B	16.84B	16.29B	13.69B	13.48B	12.88B	13.20B	13.19B	13.87B	12.81B	11.69B	11.27B	9.51B	9.14B	9.79B	9.99B	9.20B	7.58B	6.65B	5.26B	-3.78B	2.48B	2.08B	1.88B	1.52B	1.42B	1.28B	1.14B	921.50M	803.70M	582.20M	556.40M	161.30M	75.00M	49.90M	31.20M	22.00M
Interest Income	0.00	1.41B	1.20B	256.00M	753.00M	674.00M	928.00M	629.00M	603.00M	465.00M	420.00M	485.00M	448.00M	376.00M	276.00M	145.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	2.88B	1.41B	1.20B	1.26B	1.29B	1.39B	1.30B	1.26B	1.10B	1.07B	1.02B	1.05B	610.00M	604.00M	578.00M	344.00M	2.14B	2.28B	29.00M	1.06B	0.00	12.83B	0.00	0.00	0.00	0.00	134.10M	0.00	0.00	208.40M	0.00	0.00	0.00	0.00	4.70M	0.00	0.00	0.00
Depreciation & Amortization	4.07B	3.26B	3.40B	3.60B	2.21B	1.95B	1.90B	2.11B	2.11B	2.09B	1.29B	294.00M	294.00M	294.00M	294.00M	1.07B	1.20B	963.00M	841.00M	734.00M	686.50M	447.30M	265.90M	211.80M	176.80M	143.80M	117.10M	100.30M	84.20M	74.50M	50.70M	33.60M	21.50M	12.00M	8.00M	4.10M	2.60M	2.50M
EBITDA	14.70B	12.09B	12.54B	12.93B	12.63B	12.88B	12.80B	11.94B	11.13B	8.75B	7.39B	6.36B	5.05B	6.67B	6.58B	6.64B	5.98B	7.27B	5.69B	4.17B	3.78B	2.65B	1.80B	1.58B	1.50B	1.26B	1.05B	1.02B	845.00M	773.00M	601.90M	531.70M	144.90M	68.80M	3.20M	-1.50M	1.20M	1.60M
EBITDA Ratio	52.15%	33.25%	36.19%	36.95%	44.63%	46.06%	47.71%	45.34%	41.88%	33.18%	33.66%	36.81%	32.43%	41.29%	41.50%	44.44%	49.41%	50.92%	46.16%	49.19%	44.97%	228.08%	43.58%	40.71%	41.62%	43.38%	47.43%	43.85%	41.82%	53.78%	40.93%	43.19%	16.03%	19.70%	7.55%	-21.44%	-6.04%	14.69%
Operating Income	7.90B	5.34B	6.01B	5.79B	9.67B	10.26B	9.97B	9.79B	8.47B	6.19B	5.87B	5.58B	4.31B	5.55B	5.51B	5.21B	3.98B	3.84B	4.85B	3.35B	3.09B	6.31B	1.53B	1.37B	1.33B	1.12B	930.30M	916.00M	760.80M	698.50M	551.20M	498.10M	123.40M	29.10M	-4.80M	-5.60M	-1.40M	-900.00K
Operating Income Ratio	28.01%	20.27%	23.11%	22.79%	41.41%	43.22%	43.65%	42.60%	39.10%	30.86%	31.41%	32.30%	27.67%	36.84%	37.60%	34.75%	26.94%	26.91%	39.00%	31.73%	36.99%	114.20%	38.13%	39.67%	41.35%	42.33%	39.66%	41.67%	39.96%	43.12%	40.68%	46.11%	18.15%	15.28%	-6.84%	-12.64%	-4.70%	-4.27%
Total Other Income/Expenses	-42.00M	2.01B	696.00M	-1.01B	-536.00M	-718.00M	-376.00M	-631.00M	-492.00M	-606.00M	-602.00M	-960.00M	-162.00M	-228.00M	-302.00M	-199.00M	-1.64B	-1.04B	20.00M	-840.00M	81.80M	-2.89B	155.10M	306.20M	241.20M	106.00M	-68.90M	46.30M	33.60M	-110.20M	41.20M	65.00M	34.60M	43.30M	-2.60M	7.60M	3.00M	1.50M
Income Before Tax	7.86B	7.35B	6.70B	8.13B	9.14B	9.55B	9.60B	9.16B	7.98B	5.59B	5.27B	5.01B	4.15B	5.32B	5.20B	5.25B	3.96B	4.02B	4.87B	3.40B	3.17B	-684.50M	1.69B	1.67B	1.57B	1.22B	861.40M	962.30M	794.40M	588.30M	592.40M	563.10M	158.00M	29.40M	-7.40M	2.00M	1.60M	600.00K
Income Before Tax Ratio	27.86%	27.91%	25.79%	31.99%	39.11%	40.19%	42.00%	39.85%	36.83%	27.84%	28.19%	29.01%	26.63%	35.32%	35.54%	34.99%	26.82%	28.17%	39.16%	32.18%	37.97%	-12.39%	41.99%	48.55%	48.88%	46.34%	36.72%	43.78%	41.73%	36.31%	43.72%	52.12%	23.24%	15.44%	-10.54%	4.51%	5.37%	2.84%
Income Tax Expense	1.14B	794.00M	808.00M	869.00M	1.30B	1.15B	7.62B	1.44B	1.04B	427.00M	184.00M	664.00M	467.00M	690.00M	599.00M	1.05B	795.00M	1.07B	1.19B	1.03B	913.60M	707.40M	566.60M	535.80M	469.80M	361.20M	217.10M	282.50M	256.70M	268.60M	217.80M	205.50M	60.10M	10.30M	800.00K	300.00K	800.00K	100.00K
Net Income	6.72B	6.55B	5.89B	7.26B	7.84B	8.39B	1.98B	7.72B	6.94B	5.16B	5.08B	4.35B	3.68B	4.63B	4.61B	4.20B	3.17B	2.95B	3.67B	2.36B	2.26B	-1.39B	1.12B	1.14B	1.10B	863.20M	644.30M	679.80M	537.70M	319.70M	383.30M	357.60M	97.90M	19.10M	-8.20M	1.70M	800.00K	500.00K
Net Income Ratio	23.83%	24.89%	22.68%	28.57%	33.57%	35.35%	8.66%	33.59%	32.03%	25.71%	27.21%	25.17%	23.64%	30.74%	31.45%	27.97%	21.43%	20.68%	29.56%	22.40%	27.04%	-25.20%	27.88%	33.02%	34.22%	32.67%	27.47%	30.93%	28.24%	19.73%	28.29%	33.10%	14.40%	10.03%	-11.68%	3.84%	2.68%	2.37%
EPS	12.56	12.18	10.34	12.40	12.96	12.70	2.71	10.32	9.15	6.80	6.75	5.61	4.07	4.82	4.53	3.79	2.83	2.51	2.97	1.86	1.75	-1.21	1.07	1.11	1.07	0.85	0.61	0.61	0.48	0.29	0.35	0.31	0.09	0.03	-0.01	0.00	0.00	0.00
EPS Diluted	12.49	12.11	10.28	12.31	12.88	12.62	2.69	10.24	9.06	6.70	6.64	5.52	4.04	4.79	4.51	3.77	2.82	2.48	2.93	1.81	1.69	-1.21	1.03	1.05	1.02	0.82	0.59	0.61	0.47	0.28	0.35	0.31	0.09	0.03	-0.01	0.00	0.00	0.00
Weighted Avg Shares Out	535.00M	538.00M	570.00M	586.00M	605.00M	661.00M	731.00M	748.00M	758.00M	759.00M	753.00M	775.00M	905.00M	960.00M	1.02B	1.07B	1.12B	1.18B	1.24B	1.27B	1.29B	1.15B	1.05B	1.03B	1.02B	1.02B	1.06B	1.12B	1.12B	1.12B	1.10B	1.15B	1.09B	636.67M	820.00M	940.86M	940.86M	940.86M
Weighted Avg Shares Out (Dil)	538.00M	541.00M	573.00M	590.00M	609.00M	665.00M	735.00M	754.00M	766.00M	770.00M	765.00M	787.00M	912.00M	965.00M	1.02B	1.08B	1.12B	1.19B	1.26B	1.32B	1.35B	1.15B	1.08B	1.08B	1.08B	1.06B	1.10B	1.12B	1.14B	1.13B	1.10B	1.15B	1.09B	636.67M	820.00M	940.86M	940.86M	940.86M

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

November 26, 2024youtube.com

CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

November 26, 2024cnbc.com

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But the results appear to be at the low end of...

Amgen drug leads to up to 20% weight loss in trial

November 26, 2024reuters.com

Amgen's experimental drug MariTide led to average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

November 26, 2024prnewswire.com

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective...

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

November 26, 2024prnewswire.com

THOUSAND OAKS, Calif. , Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m.

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

November 22, 2024zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investing in Pharma Stocks? Check These 3 Things First

November 22, 2024fool.com

Investing in Pharma Stocks? Check These 3 Things First

Wall Street awaits Amgen weight-loss drug data expected to move shares

November 21, 2024reuters.com

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

November 20, 2024prnewswire.com

Howard Chang, M.D., Ph.D., Joins as Senior Vice President of Research and Chief Scientific Officer THOUSAND OAKS, Calif.

Amgen Sells Off: Keep Calm And Buy The Dip

November 18, 2024seekingalpha.com

Amgen's stock dropped nearly 15% last week due to safety concerns about its GLP-1 candidate MariTide. Amgen's management and analysts downplayed the bone mineral density concerns, emphasizing MariTide's potential and its ongoing Phase II study, which will be reported soon....

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Amgen Inc. (AMGN) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories